FHI Clinical announces intent to acquire South African-based CRO TCD

Transaction will see FHI Clinical become a notable player across the sub-Saharan Africa region.

Earlier today, the Durham, North Carolina-based contract research organization FHI Clinical announced its intent to acquire Triclinium Clinical Development (TCD), a South African-based CRO that is currently owned by EOH Holdings. FHI Clinical is part of FHI 360, an international non-profit organization which previously owned Novella Clinical before selling it to IQVIA in 2013. Founded as Triclinium Clinical Trial Project Management in 2000, then a niche African CRO focused primarily on regulatory and monitoring services, TCD has grown into a well-known brand across sub-Saharan Africa, particularly for its infectious diseases and vaccines expertise. Following years of growth, it was sold to Aquipharma Holdings in 2014 and then subsequently to EOH about two years later.

Through the transaction, FHI Clinical’s workforce will expand to more than 425 across the globe and will see the full-service CRO establish a presence across 12 countries. The deal will also see it expand its share of the infectious diseases market and make it a notable service provider across the sub-Saharan Africa region. “TCD’s experience and credibility in the South African market, marked by long-term client relationships and follow-on business, is a fit for our strategic vision,” said Ted FitzGerald, FHI Clinical’s Chief Executive Officer. “In addition to therapeutic alignment as an infectious disease CRO, TCD also provides the opportunity to expand our organizational ability to conduct trials in low- and middle-income countries better positioning us to repeat that success anywhere in the world.”